Citius Pharmaceuticals, Inc. 8-K

What Happened Citius Pharmaceuticals, Inc. (CTXR) filed an 8-K on February 13, 2026, furnishing a press release that announced the company’s results of operations for the first quarter of fiscal 2026. Separately, on February 9, 2026, Nasdaq notified the company that CTXR’s common stock had closed below the $1.00 minimum bid-price requirement for 30 consecutive business days and that the company has a 180-calendar-day compliance period to regain compliance.

Key Details

• Press release reporting Q1 FY2026 results was issued February 13, 2026 and is furnished as Exhibit 99.1 to the 8-K.
• Nasdaq notice dated February 9, 2026 cites noncompliance with Nasdaq Listing Rule 5550(a)(2) (minimum $1.00 bid price).
• Compliance period runs 180 calendar days, ending August 10, 2026; regaining compliance requires the bid to close at $1.00+ for at least 10 consecutive business days.
• If not regained, the company may seek a second 180-day cure period only if it meets market-value and other initial listing standards (except the bid-price rule) and notifies Nasdaq it intends to cure the deficiency — potentially via a reverse stock split. CTXR’s shares remain listed on Nasdaq under the symbol “CTXR” while the notice has no immediate listing effect.

Why It Matters For investors, the 8-K confirms the company’s quarterly results were released and highlights a material listing-risk notice from Nasdaq. A prolonged bid-price deficiency can lead to delisting proceedings, which may reduce liquidity and negatively affect share price and investor options. The notice does not change the current listing status, but there is no assurance the company will regain compliance; investors should monitor subsequent announcements (including any financial performance updates or corporate actions like a reverse split) that the company may take to address the deficiency.